Committed to the patient

Dr Antonio Parente was born in Badalona (Barcelona) and has spent most of his professional career in the pharmaceutical industry.

He studied Chemistry and earned a PhD in Organic Chemistry from the University of Barcelona (1978). His academic background also includes an MBA from ESADE (1981) and a PADE (Senior Business Management Programme) from IESE (2010). He is co-author of more than 60 scientific articles and patents.

Dr Parente began his professional career at Laboratorios Vita S.A. as Director of the R&D and Patents Department. Since 1989, he has co-founded several companies, including Lipotec S.A., BCN Peptides S.A., Diverdrugs S.L., Lipofoods S.A., BCN Corp S.L. and Primaderm S.A., where he has held several positions in their organisations, including Managing Director, CEO and board member. In 2000, he co-founded GP Pharm, where he serves as Executive Chairman.

Dr Parente has also served as President of the CRG Business Council (Centre for Genomic Regulation), Vice-President of ASEBIO (Spanish Association of Biotech Companies), co-founder and President of CataloniaBio (Catalan Association of Biotech Companies) and Vice-President of Biocat. He has also previously served as President of the Chemical-Pharmaceutical Section of the Official Association of Chemists of Catalonia (1980-1994). Finally, Dr Parente is an advisory board member and/or business angel for more than 10 Spanish biotechnology companies.

Marta Parente holds a degree in Economics and Business Administration from Pompeu Fabra University (2005) and an MBA from IESE (2010).

She began her professional career in the European Union Chamber of Commerce section in Beijing, China, working in the health and cosmetics sector (2005-2008). After completing her MBA at IESE and spending a period at Janssen Cilag S.A. in Madrid, she joined Roche in 2010, working in different areas of the company in several countries (Roche Diagnostics in Sweden, Switzerland and the United States; Roche Diabetes Care in Italy).

She later joined Genentech, the US subsidiary of Roche Pharmaceuticals, where she was responsible for global Market Access for skin cancer products in Oncology until 2015; led the US market marketing team in Oncology; and in 2017 was Head of Sales for the East / Mid-Atlantic region of the United States in Oncology at Genentech.

In 2020, she joined GP Pharm as Director of New Projects and Corporate Development, and took on the role of COO of GP Pharm in 2021. In January 2022, she was appointed CEO of GP Pharm. Marta has been a member of the company’s Board of Directors since 2017 and is a board member of BCN Peptides. In January 2024, she joined the board of CataloniaBio and, in May, the council of the Chamber of Commerce delegation in Hospitalet de Llobregat.

Anna Parente holds a degree in Medicine from the University of Barcelona (2004) and is a specialist in Haematology and Haemotherapy from Hospital de Sant Pau, where she completed her residency.

She later moved to Norway with a Kreftforeningen (Norwegian Cancer Society) grant to complete her PhD in Chronic Lymphocytic Leukaemia, titled “Unravelling the role of the microenvironment in chronic lymphocytic leukaemia: T helper cell support of cancer cells,” with Dr Ludvig Munthe’s group at the University of Oslo (2018).

She then joined Oslo University Hospital as a consultant physician, where she specialised in Immunology and has worked for the last 8 years. Her main focus has been the Cellular Immunology section, where diagnoses of haematological diseases and primary immunodeficiencies are carried out in collaboration with the departments of infectious diseases, paediatrics, haematology and clinical immunology. In 2023-24 she completed a Management Development Programme (PDD) at IESE.

Josep de Nadal was born in Barcelona and holds a degree in Chemical Engineering from the Sarrià Chemical Institute (IQS, 1968) and an MBA from ESADE (1968).

He began his professional career as Brand Manager at Danone S.A. (1968-1974), was Division Manager at MasCosmetics (1974-1976) and Managing Director of Laboratorios Ausonia (1976-1992). Josep de Nadal’s professional activities from 1992 to 2010 included a wide range of management, executive and consulting roles in several national and international companies.

Since 2010, Josep de Nadal has been a board member of Ofistrade, Senior Advisor at Clairfield Corporate Finance, board member of Sosa Ingredients SL and independent board member of GP Pharm SA. Josep de Nadal has also been a trustee of the IQS Foundation (2006-2008) and professor on the IQS Master’s Degree in Chemical Business Management (1982-1987). He is currently a member of Cercle d’Economia and Vice-President of Fundació Relleu.

Dr Berta Ponsatí was born in Barcelona and has developed her professional career in the pharmaceutical industry. She holds a degree in Chemical Sciences (1983) and a PhD in Organic Chemistry from the University of Barcelona (1985).

She has extensive training and experience in peptide chemistry, complemented by studies at the UPC (Universitat Politècnica de Catalunya) and a postdoctoral stay at the CBM (Molecular Biology Centre) in Madrid. She began her professional career as Director of the Peptide Synthesis Department at Lipotec S.A. (1990). In 2005, she became Managing Director of BCN Peptides S.A.

From 2012 to 2021, she was also Managing Director of GP Pharm S.A., where she promoted the company’s international presence, expanded its CDMO activities and consolidated its presence in the Spanish market. She is currently an independent board member of GP Pharm S.A. Dr Ponsatí is also co-author of multiple scientific articles and patents and has co-supervised several doctoral theses in the field of peptide synthesis.